
The Janus Henderson Global Life Sciences Fund Class S endeavors to achieve substantial capital appreciation over the long term. Its primary strategy involves allocating a minimum of 80% of its net assets (including any borrowed capital utilized for investment purposes) to businesses that its portfolio managers identify as having a strong life science orientation. Furthermore, as a foundational commitment to this focus, the fund has a fundamental policy to typically allocate at least 25% of its total assets to securities issued by companies formally classified within the "life sciences" sector.
Is JFNSX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
No recent news available.